Block Admission

Hutchison China Meditech Limited
22 June 2007



                  Hutchison China MediTech Limited ('Chi-Med')

                                   (AIM: HCM)


                                Block Admission


London: Friday, 22 June 2007: Chi-Med today announces that an application has
been made to London Stock Exchange plc for the block admission of 2,560,606 new
ordinary shares of US$1 each (the 'New Shares') to trade on the Alternative
Investment Market. The New Shares will represent approximately 5% of the
existing issued share capital of Chi-Med. Each of the New Shares may be
allotted and issued in due course should options granted under Chi-Med's Share
Option Scheme be exercised.

As at the date of this announcement, the issued share capital of Chi-Med is
US$51,212,121 comprising 51,212,121 ordinary shares of US$1 each.



                                      Ends



Enquiries

Chi-Med                                         Telephone: [phone]

Christian Hogg, CEO

Citigate Dewe Rogerson                          Telephone: [phone]

Anthony Carlisle                                Mobile: [phone]
Yvonne Alexander                                Mobile: [phone]



About Chi-Med


Chi-Med is the holding company of a pharmaceutical and healthcare group based
primarily in China and was admitted to trading on the Alternative Investment
Market of the London Stock Exchange in May 2006.  Chi-Med is focused on
researching, developing, manufacturing, and selling pharmaceuticals, health
supplements and other consumer health and personal care products derived from
Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international
corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.



                      This information is provided by RNS
            The company news service from the London Stock Exchange